One of the Insider's original buy recommendations -- a company much better positioned to make a fast splash on the markets than other November IPO predecessors -- will make its hotly anticipated debut before month's end.
The world's largest tobacco company just paid a 41.5% premium for a cannabis company that has been selling recreational product for less than two months. It shows the smart money is buying in on cannabis, not selling off.
The eyes of the cannabis industry continue to shift east, as Massachusetts opens its first recreational dispensaries. But a neighbor is trying to do something much bigger even without expanding beyond medical use.
With 2019 right around the corner, three key themes stand out far beyond any other topics that will shape the business end of the marijuana industry. That includes perhaps the most shocking emerging target demographic for cannabis to date.
Election Day 2018 marked another resounding victory for cannabis. After the polls closed, Michigan became the 10th state to fully legalize cannabis, while Utah and Missouri joined 31 others that have already legalized it for medical purposes. More than half of the country now has access to some form of legal marijuana thanks to this virtual “green sweep.” And right now, you have the opportunity to take this momentum all the way to the bank.
The first-ever legally approved cannabis-based drug became available to patients in the United States recently. It's a true game-changer. But it may find some stiff competition from products that aren't being reviewed by the FDA.